Kyverna Therapeutics

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company founded in 2018, with its headquarters in the United States. The company is dedicated to harnessing the power of cell therapy in autoimmune diseases. Their lead product candidate, KYV-101, is making significant strides in clinical development across rheumatology and neurology, with Phase 2 trials for multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. In addition to their current product, Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats. These therapies are designed to be well suited for use in B cell-driven autoimmune diseases, showcasing the company's commitment to innovation in the field of biotechnology. Recently, Kyverna successfully secured a $60.00M Series B investment on 03 August 2023. This investment round saw participation from industry giants such as Insight Partners, CAM Capital, Gilead Sciences, GordonMD Global Investments, LYFE Capital, Northpond Ventures, RTW Investments, Vida Ventures, Westlake Village BioPartners, and Bain Capital Life Sciences, further solidifying Kyverna's position as a promising player in the biopharmaceutical arena.